Cite
HARVARD Citation
Papadopoulos, K. et al. (n.d.). 172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors. Immuno-oncology technology. p. . [Online].